Abstract The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of testosterone and to characterize its efficacy. Testosterone release from a series of formulations was assessed in vitro. Skin from hairless mice was used in permeation experiments with Franz diffusion cells. The spray pattern, pump seal efficiency, average weight per metered dose and dose uniformity were evaluated. An optimized formulation containing 10% (w/v) testosterone, 9% (v/v) azone and 91% (v/v) ethanol was based on good skin permeation and acceptable drug concentration and permeation enhancer (PE) content. A skin irritation study indicated that the formulation was non-irritating in a rat model. An in vivo pharmacokinetic study indicated that the optimized formulation showed a different plasma concentration-time profile from that of the commercially available product Testopatch s . The Testopatch s product demonstrated a more sustainable drug release.
Introduction
Testosterone is the major circulating male androgen 1 . Testosterone deficiency is usually associated with adverse effects on body composition, bone density, sexual function and mood, and may also increase cardiovascular risk. Numerous studies have demonstrated the benefits of testosterone replacement in men with overt hypogonadism. Amongst several possible administration routes for testosterone replacement, a transdermal drug delivery system (TDDS) offers advantages over oral and intramuscular application. Hepatic first-pass metabolism in the liver after oral administration requires high testosterone doses, and potentially painful injections may lead to supra-physiological testosterone serum concentrations 2 . The relatively low molecular weight (MW¼288) and moderate lipophilicity (log P o/w ¼3.3; water solubility¼0.039 mg/mL at 37 1C) of testosterone are favorable factors for transdermal delivery 3, 4 . Gels, creams and patches are the most commonly used dosage forms for TDDS 5 . Currently, gel and patch formulations (e.g., Androgel s , Testoderm s and Androderm s ) are used clinically.
However, a gel formulation has to be applied over large surface areas to achieve the target plasma levels, and transfer of the drug to female partners has been recorded. Although the approved transdermal patches can avoid this problem, they have other drawbacks which significantly reduce patient acceptance and compliance because of skin irritation caused by occlusion 6 . The development of alternative formulations for the transdermal delivery of testosterone remains a desirable goal 7 . MDTS, which is quick drying and non-occlusive, is a better alternative to both the patch and gel systems for easy application and good tolerance. Moreover, the spray can form a "patchless drug reservoir" on the skin 8 . MDTS formulations are topical aerosols formulated as single phase solutions consisting of drug, penetration enhancers and polymers 9 . The aim of this work was to develop a safe MDTS formulation for testosterone. In vitro drug release was evaluated using skin from the hairless mouse, and the primary mechanism of drug delivery was investigated. The pharmacokinetic profile was evaluated by comparing the pharmacokinetic parameters of the optimal formulation with that of commercial product Testopatch s . The developed spray formulations were further evaluated for their performance characteristics including spray pattern, pump seal efficiency, average weight per metered dose and content per spray. A skin irritation study also was carried out using rat as an animal model. 
Materials and methods

Materials
Solubility studies
Excess testosterone was added to different solvents 10 and the resulting suspensions were shaken at 2571.0 1C for 72 h. After removal from the shaker bath, the equilibrated samples were centrifuged for 3 min at 17,800 Â g. The supernatant was filtered (pore size: 0.22 mm) prior to further examination. The sample was diluted such that the concentration was within the detection range of the instrument. Saturated concentrations were determined for each solution by HPLC using the method described below.
Formulation preparation
The MDTS formulations were developed as topical solutions made up of volatile and non-volatile vehicles containing the drug dissolved in a single phase. The non-volatile vehicle contains only permeation enhancer (PE) or combination of PE and film forming polymer (FFP). The spray system was prepared by incorporating FFP and PE into the solvent system. We used ethanol as the volatile vehicle in this study. The drug application system (Wantong Fixed Quantity Valve System Co., Ltd., Suzhou, China) consisted of a 10 mL container and an actuator with an actuating volume of 100 mL. Formulations were prepared with a series of batches using different PEs or FFPs ( Table 1 ). The selection of optimum FFP was based on drying time, cosmetical attractiveness and outward stickiness of the film formed 11 . And the selection of PE was based on transparency and non-volatility.
Characterization of the developed MDTS formulation
The characterization performed for the MDTS formulations included the evaluation of the spray pattern, effectiveness of the pump seal, average weight per metered dose and content uniformity 12 . The spray pattern was assessed by delivering the spray through the MDTS onto paper. The formulation was held at a distance of 5 cm from the paper. The wet part formed was outlined, then the outlined part was clipped from the paper. The area of the pattern was determined. Effectiveness of the pump seal was evaluated by a pump seal efficiency test. The filled containers were placed in the upright position at 301 for 3 days. The containers were weighed before and after the test period. The change in the weight of the container was recorded and the leakage rates were calculated. Average weight per metered dose was also measured. The initial weight of the container was recorded, and the container was weighed again after successive deliveries were sprayed from the MDTS. The difference between the initial and final weight of the container divided by the number of deliveries sprayed from the containers was used to represent the average weight per metered dose. The drug content per spray was determined by actuating ten sprays in a beaker containing methanol. This solution was shaken for 10 min and the drug content was analyzed by HPLC. Content uniformity was assessed by analyzing the drug content in 5th, 10th, 20th, 30th and 50th doses emitted from the pump. Guidelines for Investigations in Laboratory Animals and was approved by National Pharmaceutical Engineering and Research Center. The dorsal skin was excised after the mice were killed by cervical dislocation. Fresh prepared skin was stored in the freezer at À20 1C without repeatable freeze and thaw recycles. Prior to permeation experiments, the skin was thawed and subcutaneous fat, tissue and capillaries of the skin were carefully removed. After cutting into pieces, the skin was mounted between the donor and receptor compartment of the Franz diffusion cells with the stratum corneum facing the donor compartment.
Permeation studies
The permeation area of Franz diffusion cells was 3.14 cm 2 and the receiver volume was 7.0 mL. 40% PEG 200 was used as the receiver medium. Assembled diffusion cells in triplicate were placed in a transdermal permeation diffusion instrument and maintained isothermally at 32 1C. The receptor compartment was stirred with a magnetic stirrer at 220 rpm. The air bubbles that remained in the receptor cell were carefully removed by gentle tilting of the diffusion cells. Since the drug administration area is about 12 cm 2 (in bioequivalence study) for each pump, we used a micropipette to delivery 50 mL drug solution precisely in order to mimic the true situation of drug administration and the uniformity of drug on the skin sample. In the experiments for PE screening we applied 100 mL drug solution in order to amplify the effect of PE for observation. The system was maintained at 32 1C for 2 h. Samples of 0.3 mL were withdrawn at 2, 4, 6, 8, 10 and 24 h for HPLC analysis and an equivalent volume was added to the system to supplement the volume loss. After centrifugation at 17,800 Â g for 3 min, the supernatant was used for analysis.
In vivo animal experiments
Healthy female Sprague-Dawley rats weighing 220720 g provided by the SLAC Laboratory Animal Company Ltd. (Shanghai, China) were used in this study. The animals were housed four per cage in laminar flow that were maintained at 2272 1C and relative humidity of 50-60%. The animals were kept in these facilities for at least 1 week prior to the experiment and were fasted for at least 24 h before commencing the experiments. Before administration, the abdominal hair was shaved using an electric clipper carefully and allowed to heal for 24 h. The animals were divided into three groups with four animals in each group. The first and second groups were given the testosterone MDTS or the Testopatch s , respectively. The remaining group did not receive any treatment and served as the control group. Blood samples (250-300 mL) were collected via the retro-orbital plexus using a sterilized glass capillary tube. Before the experiments, blood samples of 300 mL were taken to measure the basal level of endogenous testosterone in each rat. After application of testosterone MDTS or the Testopatch s , blood samples were collected at the scheduled sampling times. The blood samples of rats in the control group were also collected to record the level of endogenous testosterone during the experiment. After centrifugation at 17,800 Â g for 3 min, the separated serum of 100 mL was transferred into another neat tube and frozen at À 20 1C until the determination of testosterone concentration by UPLC-MS/MS analysis.
Skin irritation study
The Draize patch test was carried out using rats as the animal model 13 . The optimized formulation was sprayed on the patch of shaven skin and occluded with adhesive tapes and the resulting reactions such as erythema and edema were scored after 24 h. The skin irritation score scale is shown in Table 2 .
Analytical method 2.8.1. HPLC analysis
The samples of testosterone in the in vitro experiments were analyzed using a HPLC system consisting of a system controller (SCL-10 ATVP; Shimadzu, Japan), a binary pump (LC-10 ATVP, Shimadzu), a UV À Vis detector (SPD-10 AVP, Shimadzu), a column oven and an auto injector (SIL-10A, Shimadzu). The separation was obtained through a C18 reversed phase analytical column (150 mm Â 4.6 mm, 5 μm) (Shimadzu, Japan) using the mobile phase consisting of methanol/water (60/40, v/v). The peak area correlated linearly with testosterone concentration in the range 1-100 mg/mL. The obtained linear equation is A¼ 73,624C -56,654 (R 2 ¼0.999). The coefficient of variation (CV) was below 2% at three levels of 5, 25 and 100 μg/mL.
In vivo UPLC-MS/MS analysis of testosterone
The analyte was recovered from the plasma samples by liquid-liquid extraction (LLE) after thawing thoroughly at room temperature. 14 Briefly, 10 μL of testosterone propionate solution was added to the serum sample as an internal standard and mixed well by vortexing, and then LLE was performed by the addition of tert-butyl methyl ether followed by vortex extraction for 3 min. After centrifugation at 17,800 Â g for 5 min, the upper organic layer was transferred into a clean tube and evaporated to dryness at 40 1C with a vacuum centrifugal concentrator (miVac DUO, Genevac). The residue was reconstituted with 200 mL of mobile phase and mixed by vortexing for 30 s. Analysis of testosterone was performed with UPLC-MS/MS system equipped with a system controller (SCL-10 ATVP; Shimadzu), a binary pump (LC-10 ATVP; Shimadzu), a UV-Vis detector (SPD-10 AVP, Shimadzu), a column oven and an auto injector (SIL-10A; Shimadzu) with an electrospray ionization (ESI) interface. The UPLC separation was obtained through a C18 reversed phase analytical column (Shim-pack XR-ODS III) (2.0 mm Â 75 mm, 1.6 mm) using a mobile phase of methanol and 10 mM ammonium acetate buffer at a flow rate of 0.3 mL/min. The column temperature was set at 40 1C, detection wavelength at 241 nm and an injection volume of 10 mL. A gradient elution was carried out as shown in Table 3 .
The MS/MS conditions were set as follows: The ionization method was ESI, which was operated in positive single ion monitoring (SIMþ) mode. Nitrogen was used as the nebulizer and desolvation gas with a flow rate of 3 and 15 L/min. The capillary temperature and voltage were set at 400 1C and 3.0 kV. Desolvation temperature was 400 1C. Quantification was performed using the multiple reaction monitoring mode with a transition of m/z 289.25-109.20 for testosterone and m/z 345.30-109.20 for the internal standard. The data were acquired and analyzed by Shimadzu Labsolutions software. Retention times were 2.870.1 and 3.270.1 min for the internal standard and testosterone, respectively. The analytical column and mobile phase used for the assay provided a clear separation between testosterone and the internal standard. There was no interference from any endogenous material. The limit of detection by this method was 1 ng/mL. The method recovery rate was 100.8071.87%, and the extraction recovery rate was 80.4573.21%. The intra-day and inter-day assay coefficients of variation were 1.89% and 3.68%, demonstrating good reproducibility.
Data analysis
The cumulative amount Q (μg/cm 2 ) of testosterone that permeated through skin was calculated by
where A is the effective area, V is the volume of receptor cell, C n is the drug concentration at time point "n", V 0 is the volume of receptor cell, and C i is the testosterone concentration at time point "i". The cumulative amount of testosterone that permeated through the skin was plotted versus time (h). Each data point was expressed as the mean7SD of three determinations. The flux data were subjected to student's t-test and one-way analysis of variance (ANOVA) to determine the level of significance. The data was considered to be significant if Po0.05. The enhancement ratio (ER) was determined using the following equation:
ER ¼ Flux with enhancer =Flux without enhancer ð2Þ
Peak plasma concentration during the dosing period (C max ) and the time of peak plasma concentration (T max ) was directly determined from the pharmacokinetic data. The pharmacokinetic parameters such as area under curve (AUC 0 À t ), half-life of elimination from plasma (t 1/2 ) and mean residence time (MRT) were calculated by noncompartment analysis following transdermal application using DAS 2.0 software. Relative bioavailability F (%) was calculated from
Ádose optimal formulationÞ Â 100% ð3Þ
The drug administration area of each pump was calculated by
where W 0 and A 0 is the known weight and area of the piece that was clipped from the paper; W x is the weight of the paper after certain MDTS actuation; and A x is the area of the pump. Taking paper with area of 10 cm Â 10 cm and weighted 0.8166 g as a sample, W 0 is 0.8166 g, A 0 is 100 cm 2 .
Results and discussion
Solubility
To ensure stable collection conditions, a 40% (v/v) PEG water solution was used as the receptor fluid. Based on the hypothesis that PE acts as a "transporter vehicle" for the drug, the solubility of testosterone in different PE can be one of the criterions for the PE screening. The more drug solubilized in the vehicle, the higher was the transdermal flux 15, 16 . From the results shown in Table 4 , the solubility of testosterone in different PEs is NMP4PG4azone4IPM. NMP showed the greatest solubility for testosterone, and NMP subsequently was used as a solubilizer in most cases. PG and azone showed similar ability to solubilize testosterone.
Preparation of MDTS
Based on the practical application of MDTS, we took 2 min as the critical point for the drying time of the film formed. For the measurement of stickiness, there should not be fiber left on the film when pressing some cotton on the film for 1 min. The film formed by the formulation incorporating FFP was transparent and cohesive (Table 5) . By varying the ratio of the FFP, based on the visualization of the film formed, we chose 5% as the content of FFP. All formulations containing PE or both FFP and PE were clear in appearance. The flow rate was 0.3 mL/min. a Methanol. b 10 mM ammonium acetate buffer.
In vitro evaluation
The effects of FFP, PE, testosterone concentration and the PE content on skin permeation were investigated to optimize the testosterone MDTS formulation.
Effect of FFP on skin permeation
The transdermal permeation profiles of formulations containing different FFPs showed that their transdermal flux is higher than that of the control group, the ER for each formulation containing FFP was Plasdone s S6304Eudragit s E PO4PVP K304Eudra-git s RL (Fig. 1) . This might be attributed to the fact that FFP delayed the crystallization of testosterone after its administration and lead to greater transdermal flux. These results supported the finding that these materials had the ability to inhibit the drug crystallization 17,18 .
Effect of PE on skin permeation
Among the PEs studied in this experiment, azone showed the greatest transdermal flux (Fig. 2) . The ER for each formulation containing PE was azone4IPM4PG4NMP. Although NMP showed the greatest solubilizing ability for testosterone, NMP can also be functioned as solubilizer. The solubility of testosterone in NMP was 518.9 mg/mL, much higher than the others, which can be attributed to this reason. Trottet et al. 19 had shown that PG would permeate though the skin and might carry the drug with it, as shown by correlations in vitro between the permeation of both PG and drug. The investigation of the influence of PE on drug permeation from volatile formulations reconfirmed the conclusion stated by Trottet et al. Hadgraft et al. 20 reported that IPM remained in the skin after administration to form a "patchless drug reservoir" instead of permeating through the skin as with PG. Azone is nonirritant to human skin, even in undiluted form, reversible in its action and hardly absorbed through human skin 21 . The permeation enhancement ability of azone was higher than IPM. Since we found that IPM showed the greatest permeation ability during the development of a pressure sensitive adhesive (PSA) patch for testosterone, it seems that the contradictory results suggest different mechanisms between the two dosage forms we developed. This indicates that the solubility of testosterone in PE is a critical factor in determination of transdermal flux.
Effect of testosterone and azone with various concentrations
Plasdone s S630 showed the greatest transdermal drug flux in the investigation of the effect of FFP on skin permeation, as shown in Fig. 1 . It almost stopped drug release during 10-24 h. While the formulation containing azone showed continuous release during 0-24 h. This difference might be attributed to the different mechanism which needed further investigation. So we selected formulation containing testosterone and azone without Plasdone s S630 for further optimization. By changing the concentrations of testosterone and azone, the results indicated that the transdermal flux of testosterone responded positively with the ratio of azone when the drug is at a relatively low concentration of 5% or 10% (Fig. 3 ). This might be attributed to that the solubilized drug increased with the use of azone, and as a result the transdermal flux increased. When the drug concentration reached a relative high level of 15%, the transdermal flux was greatest when the azone ratio was 5%, but the percutaneous permeation profiles of testosterone were similar to those where the azone ratio was 7% and 9% 22, 23 . It may be that the azone was not able to carry the drug into the skin fast enough after the volatile solvent evaporated, and the crystallization of the drug outside the skin warrants investigation 24 .
In vivo evaluation
Based on the above results, a formulation containing 10% w/v testosterone, 9% v/v azone and 91% v/v ethanol was selected as optimal. To compare the newly developed testosterone MDTS to the commercial product Testopatch s in pharmacokinetic profile, a bioavailability study was carried out in female rats. Fig. 4 depicts the profiles of mean plasma concentration of testosterone versus time following the transdermal application of experimental MDTS (100 mL, 12 cm 2 , 10 mg) and Testopatch s (0.5 mg/cm 2 , 12 cm 2 , 6 mg). We chose 100 mL as the dosage of experimental MDTS to ensure the integrity of each actuation. Since the administration area of each actuation is 12 cm 2 , we also delivered 12 cm 2 drug administration area for Testopatch s . The profile of blank serum sample of rats without testosterone administration was also determined. The results indicate that plasma testosterone concentrations increased promptly after administration and reached the peak level; thereafter the plasma concentrations gradually declined. The results with the control group showed that the effect of endogenous testosterone was limited. The pharmacokinetic parameters were calculated using a non-compartmental model and presented in Table 6 . Compared with the testosterone MDTS group, the Testopatch s group showed a more steady plasma concentration profile. This difference might be attributed to the different transdermal mechanisms of these two dosage forms. In the testosterone MDTS group, the drug reservoir was formed in the skin after the drug administration. Once the reservoir formed, there was no extra drug to supply for the reservoir. For the Testopatch s group, the reservoir remained until the patch was removed. After the peak level was reached, the testosterone in MDTS group declined more quickly in the absence of a patch resevoir. The relative bioavailability (F) was 79.78% for the testosterone MDTS. Traditional TDDS products relied mainly on their occlusive nature to increase the permeability of the drug candidates. Occlusion often causes an increased possibility of skin irritation at the application site. Occlusive systems can also provide an environment for microbial proliferation 25 . Besides, manufacturing and scale-up of multi-component patches has caused some distinct challenges to the formulator. Additionally, issues on formulation stability and drug crystallization on longer-term storage are still to be solved. MDTS represents an evaporative system which provides passive and nonocclusive delivery 26 . As a result of these characteristics, this system demonstrates very low skin irritation rates. This formula also enables the formulation a uniform distribution on the skin over a defined area after application. Comparing with the patch, the manufacturing and scale-up of MDTS is much easier. As the MDTS is easy to use, well tolerated and can avoid the skin irritation caused by the occlusive environment. The advantage of this dosage form would make up its relative low bioavailability.
Characterization of the MDTS formulation
In this study, we evaluated the drug administration of each pump. The results indicated that this MDTS formulation showed a uniform spray pattern (Table 7) .
No leakage was observed from the MDTS containers when placed in the upright position at 301 for 3 d. Content uniformity was assessed for the 5th, 10th, 20th, 30th and 50th doses and the results indicated that the MDTS provides uniform content per actuation. Average weight per metered dose is an important quantitative parameter and the testosterone content per spray was also determined. The results indicated that the testosterone MDTS showed reproducible amounts of the formulation per actuation (Table 8 ).
Skin irritation study
No erythema or edema was found in the primary skin irritation studies with the optimized formulations (10% testosterone, 9% azone and 91% ethanol) on rat skin.
Conclusions
A novel transdermal drug delivery system was designed and evaluated in vitro and in vivo. The effects of FFPs, PEs, testosterone concentration and the content of enhancer azone on skin permeation were investigated to identify an optimized formulation. The final formulation provided satisfactory skin permeation with an appropriate combination of testosterone and azone content. The pharmacokinetic parameters of the optimal formulation showed a different plasma profile from that of a commercial product, indicating a likely different transdermal mechanism, which needs further investigation. Characterization of the testosterone MDTS indicated that it could deliver reproducible amounts of the formulation per actuation. No erythema or edema was found in the primary skin irritation studies with the optimized formulations in rats, and hence this application system was found to be safe and non-irritating for transdermal application. From the results obtained in this work it can be concluded that the MDTS has potential as an alternative therapeutic system for the transdermal delivery of testosterone. 
